Comparing two bronchodilators combined (LABA/LAMA) to the standard therapy, that uses a combination of a long acting beta agonist and inhaled corticosteroid – Salmeterol and Fluticasone (ICS/LABA). Findings from the study were published in the New England journal of Medicineearlier this year.The trial showed that Indacaterol/glycopyrronium (LABA/LAMA) was superior to the current recommended COPD exacerbations Treatment for the whole spectrum of exacerbation symptoms tested, with a good safety profile and less episodes of pneumonia. Professor Wedzicha was the PI for the trial and it was sponsored by Novartis.
COPD exacerbations play an important role in this disease management as they affect disease progression, hospital admissions and are costly to healthcare services. The assessment of COPD exacerbations during the trial involved the methodology developed by Prof Wedzicha and her research team and used in the London COPD exacerbation cohort based at Imperial College. The results of this trial will now have major implications for Copd Exacerbations patients and COPD exacerbations Treatment algorithms in guidelines will need to be revised. This should help improve the healthcare and quality of life for COPD patients .source